Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	91591
Country	Australia

Received	2023-12-31 12:31
Peer-Review Started	2023-12-31 12:31
To Make the First Decision
Return for Revision	2024-02-06 00:51
Revised	2024-02-28 13:14
Second Decision	2024-04-10 02:34
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2024-04-10 05:56
Articles in Press	2024-04-10 05:56
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-04-19 09:32
Publish the Manuscript Online	2024-04-24 07:42

ISSN	2150-5349 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Treatment endpoints in ulcerative colitis: Does one size fit all?
Manuscript Source	Invited Manuscript
All Author List	Nikola Mitrev and Viraj Kariyawasam
Funding Agency and Grant Number
Corresponding Author	Nikola Mitrev, BSc, FRACP, MBBS, MPhil, Doctor, Department of Gastroenterology, Blacktown Hospital, 18 Blacktown Road, Blacktown 2148, NSW, Australia. nikola.m@hotmail.com
Key Words	Ulcerative colitis; Treatment endpoints; Endoscopic remission; Histologic remission; Biomarkers; Gut barrier healing
Core Tip	Recently, more stringent treatment endpoints have emerged such as histologic remission and functional gut barrier healing, which may be better predictors of clinically important outcomes compared to mucosal healing. However, pursuing deeper levels of remission in ulcerative colitis patients can have risks. Treatment endpoints in ulcerative colitis should be set with two thresholds, minimum and ideal endpoints to be achieved. Endpoints also need to be appropriate for both the follow up timeframe and the treatment selected. Individual patient circumstances need to be taken into account in selecting endpoints, as at times relaxed treatment endpoints are appropriate.
Publish Date	2024-04-24 07:42
Citation	Mitrev N, Kariyawasam V. Treatment endpoints in ulcerative colitis: Does one size fit all? World J Gastrointest Pharmacol Ther 2024; 15(2): 91591
URL	https://www.wjgnet.com/2150-5349/full/v15/i2/91591.htm
DOI	https://dx.doi.org/10.4292/wjgpt.v15.i2.91591

Full Article (PDF)	WJGPT-15-91591-with-cover.pdf
Full Article (Word)	91591.docx
Manuscript File	91591_Auto_Edited-LJH-YJP.docx
Answering Reviewers	91591-Answering reviewers.pdf
Audio Core Tip	91591-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	91591-Conflict-of-interest statement.pdf
Copyright License Agreement	91591-Copyright license agreement.pdf
Peer-review Report	91591-Peer-review(s).pdf
Scientific Misconduct Check	91591-Bing-Liu JH-2.png
Scientific Misconduct Check	91591-CrossCheck.png
Scientific Editor Work List	91591-Scientific editor work list.pdf